Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 701.85 USD -0.9% Market Closed
Market Cap: 77.1B USD
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 1 108.02 USD with a low forecast of 808 USD and a high forecast of 1 291.5 USD.

Lowest
Price Target
808 USD
15% Upside
Average
Price Target
1 108.02 USD
58% Upside
Highest
Price Target
1 291.5 USD
84% Upside

REGN Last Price Targets
Regeneron Pharmaceuticals Inc

The latest public price target was made on Nov 1, 2024 by Christopher Raymond from Piper Sandler , who expects REGN stock to rise by 70% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Christopher Raymond
Piper Sandler
1 195 USD
Upside 70%
1 month ago
Nov 1, 2024
Regeneron Pharma (REGN) PT Lowered to $1,195 at Piper Sandler
StreetInsider
Andrew Berens
Leerink Partners
880 USD
Upside 25%
1 month ago
Nov 1, 2024
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
StreetInsider
Evan David Seigerman
BMO Capital
1 190 USD
Upside 70%
1 month ago
Nov 1, 2024
Regeneron Pharma (REGN) PT Lowered to $1,190 at BMO Capital
StreetInsider
Cory Kasimov
Evercore ISI
1 170 USD
Upside 67%
1 month ago
Oct 31, 2024
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
StreetInsider
Cory Kasimov
Evercore ISI
1 175 USD
Upside 67%
1 month ago
Oct 24, 2024
Regeneron Pharma (REGN) PT Lowered to $1,175 at Evercore ISI
StreetInsider
Mohit Bansal
Wells Fargo
1 050 USD
Upside 50%
2 months ago
Oct 23, 2024
Regeneron Pharma (REGN) PT Lowered to $1,050 at Wells Fargo
StreetInsider
Thomas Klee
Truist Financial
1 200 USD
Upside 71%
2 months ago
Sep 24, 2024
Regeneron weakness to Amgen injuction ruling an 'overreaction', says Truist
TheFly
Brian Skorney
Robert W. Baird
940 USD
Upside 34%
2 months ago
Sep 24, 2024
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
StreetInsider
Salveen Richter
Goldman Sachs
1 292 USD
Upside 84%
2 months ago
Sep 24, 2024
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
StreetInsider
David Risinger
Leerink Partners
1 077 USD
Upside 53%
2 months ago
Sep 24, 2024
Regeneron downgraded to Market Perform from Outperform at Leerink
TheFly
Evan David Seigerman
BMO Capital
1 300 USD
Upside 85%
3 months ago
Sep 12, 2024
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
StreetInsider
Brian Abrahams
RBC Capital
1 282 USD
Upside 83%
3 months ago
Sep 9, 2024
Regeneron price target raised to $1,282 from $1,250 at RBC Capital
TheFly
Christopher Raymond
Raymond James
1 242 USD
Upside 77%
4 months ago
Aug 23, 2024
Regeneron price target raised to $1,242 from $1,166 at Piper Sandler
TheFly
Geoff Meacham
Bank of America Securities
805 USD
Upside 15%
4 months ago
Aug 2, 2024
Regeneron price target raised to $805 from $720 at BofA
TheFly
Brian Abrahams
RBC Capital
1 240 USD
Upside 77%
4 months ago
Aug 2, 2024
Regeneron price target raised to $1,240 from $1,232 at RBC Capital
TheFly
Christopher Raymond
Raymond James
1 166 USD
Upside 66%
5 months ago
Jul 19, 2024
Regeneron Pharma (REGN) PT Raised to $1,166 at Piper Sandler
StreetInsider
Yatin Suneja
Guggenheim
1 180 USD
Upside 68%
5 months ago
Jul 18, 2024
Regeneron price target raised to $1,180 from $1,040 at Guggenheim
TheFly
Trung Huynh
UBS
1 250 USD
Upside 78%
5 months ago
Jul 12, 2024
Regeneron price target raised to $1,250 from $1,124 at UBS
TheFly
Terence Flynn
Morgan Stanley
1 182 USD
Upside 68%
5 months ago
Jul 11, 2024
Regeneron price target lowered to $1,182 from $1,183 at Morgan Stanley
TheFly
Jasper Hellweg
Argus Research
1 170 USD
Upside 67%
5 months ago
Jun 25, 2024
Regeneron price target raised to $1,170 from $1,060 at Argus
TheFly
Brian Abrahams
RBC Capital
1 299 USD
Upside 85%
6 months ago
Jun 13, 2024
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Benzinga
Brian Abrahams
RBC Capital
1 229 USD
Upside 75%
6 months ago
Jun 12, 2024
Regeneron price target raised to $1,229 from $1,200 at RBC Capital
TheFly
Brian Abrahams
RBC Capital
1 200 USD
Upside 71%
6 months ago
Jun 4, 2024
Regeneron Pharma (REGN) PT Raised to $1,200 at RBC Capital
StreetInsider
Evan David Seigerman
BMO Capital
1 082 USD
Upside 54%
6 months ago
Jun 3, 2024
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
StreetInsider
Christopher Raymond
Raymond James
1 000 USD
Upside 42%
7 months ago
May 20, 2024
Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
StreetInsider
Cory Kasimov
Evercore ISI
1 150 USD
Upside 64%
7 months ago
May 13, 2024
Evercore ISI Starts Regeneron Pharma (REGN) at Outperform
StreetInsider
Brian Abrahams
RBC Capital
1 185 USD
Upside 69%
7 months ago
May 3, 2024
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
StreetInsider
Akash Tewari
Jefferies
1 060 USD
Upside 51%
8 months ago
Apr 12, 2024
Regeneron Pharma (REGN) PT Raised to $1,060 at Jefferies
StreetInsider
Brian Abrahams
RBC Capital
1 189 USD
Upside 69%
8 months ago
Apr 11, 2024
RBC on Regeneron Pharma (REGN):'The Buying Opportunity Many Have Been Looking For, With Overdone DOJ Downside On Top Of Recent Weakness'
StreetInsider
Matthew Harrison
Morgan Stanley
1 115 USD
Upside 59%
9 months ago
Mar 13, 2024
Regeneron Pharma (REGN) PT Raised to $1,115 at Morgan Stanley, 'Numerous catalysts ahead; refreshing estimates'
StreetInsider
Brian Abrahams
BMO Capital
1 076 USD
Upside 53%
11 months ago
Jan 12, 2024
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Benzinga
Andrew Berens
Leerink Partners
976 USD
Upside 39%
1 year ago
Mar 27, 2023
SVB Leerink Upgrades Regeneron Pharma (REGN) to Outperform
StreetInsider
Akash Tewari
Jefferies
925 USD
Upside 32%
1 year ago
Mar 24, 2023
Jefferies Upgrades Regeneron Pharma (REGN) to Buy
StreetInsider
Unknown Analyst
EF Hutton
853 USD
Upside 22%
1 year ago
Feb 8, 2023
EF Hutton Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $853
Benzinga
Unknown Analyst
RBC Capital
787 USD
Upside 12%
1 year ago
Feb 6, 2023
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $787
Benzinga
Unknown Analyst
Leerink Partners
834 USD
Upside 19%
1 year ago
Feb 6, 2023
SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $834
Benzinga
Unknown Analyst
Morgan Stanley
883 USD
Upside 26%
1 year ago
Feb 6, 2023
Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $883
Benzinga
Show More Price Targets
Show Less Price Targets
Christopher Raymond
Piper Sandler
Price Target 1 195 USD
Upside/Downside 70%
View Source
Andrew Berens
Leerink Partners
Price Target 880 USD
Upside/Downside 25%
View Source
Evan David Seigerman
BMO Capital
Price Target 1 190 USD
Upside/Downside 70%
View Source
Cory Kasimov
Evercore ISI
Price Target 1 170 USD
Upside/Downside 67%
View Source
Cory Kasimov
Evercore ISI
Price Target 1 175 USD
Upside/Downside 67%
View Source
Mohit Bansal
Wells Fargo
Price Target 1 050 USD
Upside/Downside 50%
View Source
Thomas Klee
Truist Financial
Price Target 1 200 USD
Upside/Downside 71%
View Source
Brian Skorney
Robert W. Baird
Price Target 940 USD
Upside/Downside 34%
View Source
Salveen Richter
Goldman Sachs
Price Target 1 292 USD
Upside/Downside 84%
View Source
David Risinger
Leerink Partners
Price Target 1 077 USD
Upside/Downside 53%
View Source
Evan David Seigerman
BMO Capital
Price Target 1 300 USD
Upside/Downside 85%
View Source
Brian Abrahams
RBC Capital
Price Target 1 282 USD
Upside/Downside 83%
View Source
Christopher Raymond
Raymond James
Price Target 1 242 USD
Upside/Downside 77%
View Source
Geoff Meacham
Bank of America Securities
Price Target 805 USD
Upside/Downside 15%
View Source
Brian Abrahams
RBC Capital
Price Target 1 240 USD
Upside/Downside 77%
View Source
Christopher Raymond
Raymond James
Price Target 1 166 USD
Upside/Downside 66%
View Source
Yatin Suneja
Guggenheim
Price Target 1 180 USD
Upside/Downside 68%
View Source
Trung Huynh
UBS
Price Target 1 250 USD
Upside/Downside 78%
View Source
Terence Flynn
Morgan Stanley
Price Target 1 182 USD
Upside/Downside 68%
View Source
Jasper Hellweg
Argus Research
Price Target 1 170 USD
Upside/Downside 67%
View Source
Brian Abrahams
RBC Capital
Price Target 1 299 USD
Upside/Downside 85%
View Source
Brian Abrahams
RBC Capital
Price Target 1 229 USD
Upside/Downside 75%
View Source
Brian Abrahams
RBC Capital
Price Target 1 200 USD
Upside/Downside 71%
View Source
Evan David Seigerman
BMO Capital
Price Target 1 082 USD
Upside/Downside 54%
View Source
Christopher Raymond
Raymond James
Price Target 1 000 USD
Upside/Downside 42%
View Source
Cory Kasimov
Evercore ISI
Price Target 1 150 USD
Upside/Downside 64%
View Source
Brian Abrahams
RBC Capital
Price Target 1 185 USD
Upside/Downside 69%
View Source
Akash Tewari
Jefferies
Price Target 1 060 USD
Upside/Downside 51%
View Source
Brian Abrahams
RBC Capital
Price Target 1 189 USD
Upside/Downside 69%
View Source
Matthew Harrison
Morgan Stanley
Price Target 1 115 USD
Upside/Downside 59%
View Source
Brian Abrahams
BMO Capital
Price Target 1 076 USD
Upside/Downside 53%
View Source
Andrew Berens
Leerink Partners
Price Target 976 USD
Upside/Downside 39%
View Source
Akash Tewari
Jefferies
Price Target 925 USD
Upside/Downside 32%
View Source
Unknown Analyst
EF Hutton
Price Target 853 USD
Upside/Downside 22%
View Source
Unknown Analyst
RBC Capital
Price Target 787 USD
Upside/Downside 12%
View Source
Unknown Analyst
Leerink Partners
Price Target 834 USD
Upside/Downside 19%
View Source
Unknown Analyst
Morgan Stanley
Price Target 883 USD
Upside/Downside 26%
View Source
Show More Price Targets
Show Less Price Targets
Regeneron Pharmaceuticals Inc Competitors:
Price Targets
INCY
Incyte Corp
17% Upside
096530
Seegene Inc
65% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
78% Upside
ITOS
Iteos Therapeutics Inc
374% Upside
ACAD
ACADIA Pharmaceuticals Inc
52% Upside
IDYA
IDEAYA Biosciences Inc
118% Upside
PROB
Probi AB
38% Downside
002007
Hualan Biological Engineering Inc
18% Upside

Revenue
Forecast

Revenue Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 16%. The projected CAGR for the next 4 years is 8%.

16%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 17%. The projected CAGR for the next 4 years is 14%.

17%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Net Income
Forecast

Net Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 26%. The projected CAGR for the next 4 years is 13%.

26%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-17%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is REGN's stock price target?
Price Target
1 108.02 USD

According to Wall Street analysts, the average 1-year price target for REGN is 1 108.02 USD with a low forecast of 808 USD and a high forecast of 1 291.5 USD.

What is Regeneron Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 16%. The projected CAGR for the next 4 years is 8%.

What is Regeneron Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 17%. The projected CAGR for the next 4 years is 14%.

What is Regeneron Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 26%. The projected CAGR for the next 4 years is 13%.

Back to Top